openPR Logo
Press release

Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe

06-29-2017 04:15 PM CET | Health & Medicine

Press release from: Agena Bioscience

/ PR Agency: akampion
-- MassARRAY® System with Chip Prep Module receives CE-IVD marking for general in vitro diagnostic use in Europe --

San Diego, CA, June 29, 2017– Agena Bioscience today announced the European launch of the MassARRAY® System with CHIP Prep Module (CPM), marketed as a CE-IVD product under the Directive 98/79/EC for in vitro diagnostic medical devices.
The MassARRAY Dx product offers clinical laboratories a unique combination of reliability, sensitivity, ease of use, and cost-effectiveness for targeted genetic testing. The multiplexing feature of MassARRAY supports assays that interrogate multiple biomarkers in a single reaction, which reduces the cost and turnaround time compared with other diagnostic methods. The system enables high-throughput, accurate detection of SNPs, INDELs, and copy number variations across a variety of genetic applications, including mutation profiling for solid tumors and highly sensitive liquid biopsy analysis, and comprehensive pharmacogenomics profiling. The flexibility and scalability of the platform facilitate easy development of custom panels and validation across large numbers of samples.
“This is good news and a new step for this high performing in vitro diagnostic (IVD) device. It will facilitate implementation in clinical labs and accreditation,” said Dr. Pierre-Jean Lamy, Directeur Général, Biologiste Médical at Labosud Oc Biologie.
“This is another great milestone in Agena’s global strategy to grow the clinical business by offering laboratories a highly effective diagnostic platform that can support the rapidly evolving needs of this market,” said Peter Dansky, Chief Executive Officer of Agena Bioscience. “In addition to the well-established performance of the MassARRAY System, the Chip Prep Module now adds increased ease-of-use to the overall workflow”.
The new CE-IVD marked MassARRAY System with Chip Prep Module joins the company’s growing line of in vitro diagnostic devices for certain European countries, including the MassARRAY Dx Analyzer 4, MassARRAY Dx Nanodispenser, MassARRAY Dx Colon Panel and MassARRAY Dx Lung Panel. These are sold exclusively in Europe for diagnostic use, and are not available for sale in the United States.

###

About Agena Bioscience
Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. For more information about Agena, visit www.agenabio.com.

Media Contact:
Agena Bioscience
Mickie Henshall
4755 Eastgate Mall,
San Diego, CA 92121
USA
(858) 882-2707
mickie.henshall(at)agenabio.com

akampion
Dr. Ludger Wess / Ines-Regina Buth
Tel: +49 40 8816 5964
Tel: +49 30 2363 2768
info(at)akampion.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe here

News-ID: 602568 • Views:

More Releases from Agena Bioscience

Agena Bioscience Launches High-Throughput, Low-Cost SARS-CoV-2 Detection Panel i …
San Diego, CA, September 28, 2020 - Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, today announced that it has obtained CE-IVD marking for its SARS-CoV-2 Panel, an in vitro diagnostic test for the qualitative detection of the SARS-CoV-2 coronavirus that causes COVID-19. Clinical laboratories can process more than 6000 samples each day running the assay on a single MassARRAY® instrument, making it one of
Agena Bioscience and Intermountain Healthcare Announce Research Collaboration to …
12 July 2017 SAN DIEGO, CA, AND SAINT GEORGE, UTAH – Agena Bioscience and Intermountain Healthcare announced today a strategic collaboration that focuses on expanding the use of Agena’s MassARRAY® System in oncology applications. The collaboration concentrates on expansion of Agena’s technology with the goal of focused panels for liquid and tissue biopsy. The molecular tests augment laboratory services available worldwide from Intermountain Precision Genomics to advance precision medicine in
AGENA BIOSCIENCE ANNOUNCES EXPANDED PARTNERSHIP WITH ASSUREX HEALTH
-- MassArray® System Selected for Assurex Health’s GeneSight Test -- San Diego, CA, June 20, 2017– Agena Bioscience today announced that Assurex Heath, a wholly owned subsidiary of Myriad Genetics, Inc., has selected the MassARRAY® System for streamlined laboratory set-up and sample processing of Assurex Health’s GeneSight test. The GeneSight Psychotropic test helps clinicians select appropriate medications for patients with depression and other mental health conditions by analyzing how a patient’s

All 4 Releases


More Releases for MassARRAY

Agena Bioscience Launches High-Throughput, Low-Cost SARS-CoV-2 Detection Panel i …
San Diego, CA, September 28, 2020 - Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, today announced that it has obtained CE-IVD marking for its SARS-CoV-2 Panel, an in vitro diagnostic test for the qualitative detection of the SARS-CoV-2 coronavirus that causes COVID-19. Clinical laboratories can process more than 6000 samples each day running the assay on a single MassARRAY® instrument, making it one of
2019 SNP Genotyping and Analysis Market Currect Statistics and Future Growth by …
"Global SNP Genotyping and Analysis Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of SNP Genotyping and Analysis market with detailed market segmentation by Technology, Application and geography. The global SNP Genotyping and Analysis market is expected to witness high growth during the forecast period. The report
Global SNP Genotyping and Analysis Market Professional Survey, Growth, Trends & …
Market Research Hub (MRH) has included a new research report titled “The Global SNP Genotyping and Analysis Market Professional Survey Report 2017”, provides detailed analysis of market size, trend, demand, revenue, growth, and segmentation of the global SNP Genotyping and Analysis industry in the coming forecast Period From 2017-2022. Also, the Regional market exploration is provided for global regions including Asia-Pacific, Western Europe, North America and China. Request Free Sample
SNP Genotyping and Analysis Market 2017: Industry Demand, Insight & Forecast By …
ReportsMonitor.com has added a new report to its database Global SNP Genotyping and Analysis Market Research Report 2017 DOWNLOAD SAMPLE PAGES @ https://www.reportsmonitor.com/request-sample/?post=300161 Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of SNP Genotyping and Analysis in these regions, from 2012 to 2022 (forecast), covering North America Europe China Japan Southeast Asia India Global SNP Genotyping and Analysis market competition by top manufacturers, with production, price, revenue
Agena Bioscience and Intermountain Healthcare Announce Research Collaboration to …
12 July 2017 SAN DIEGO, CA, AND SAINT GEORGE, UTAH – Agena Bioscience and Intermountain Healthcare announced today a strategic collaboration that focuses on expanding the use of Agena’s MassARRAY® System in oncology applications. The collaboration concentrates on expansion of Agena’s technology with the goal of focused panels for liquid and tissue biopsy. The molecular tests augment laboratory services available worldwide from Intermountain Precision Genomics to advance precision medicine in
AGENA BIOSCIENCE ANNOUNCES EXPANDED PARTNERSHIP WITH ASSUREX HEALTH
-- MassArray® System Selected for Assurex Health’s GeneSight Test -- San Diego, CA, June 20, 2017– Agena Bioscience today announced that Assurex Heath, a wholly owned subsidiary of Myriad Genetics, Inc., has selected the MassARRAY® System for streamlined laboratory set-up and sample processing of Assurex Health’s GeneSight test. The GeneSight Psychotropic test helps clinicians select appropriate medications for patients with depression and other mental health conditions by analyzing how a patient’s